Brandenburg Kapital - News about Lindis Blood Care GmbH

Lindis Blood Care Initiates Clinical EU Certification Study


Henningsdorf/Berlin - März 2021. Lindis Blood Care, a portfolio company of Brandenburg Kapital that aims to revolutionize blood management during cancer surgeries with its medical device CATUVAB® for the removal of tumor cells from surgical shed blood, on the 18th of March announced the start of its multicenter study REMOVE. The study is intended to confirm the positive results of a preliminary exploratory study and thus lay the basis for European CE certification as a medical device. First patients have already been enrolled at trial sites in Germany.

Brandenburg Kapital GmbH has been supporting the company since 2019.

Please read more information about Lindis Blood Care GmbH below in the download section.

About Lindis Blood Care:

Lindis Blood Care is a medical technology company developing the medical device CATUVAB®. CATUVAB® is used to remove EpCAM-positive tumor cells from surgical blood with the use of MAT (machine autotransfusion) technology, which is generally used today to re-transfuse surgical shed blood in non-oncological procedures. The product and process can be integrated easily into everyday clinical practice and become part of contemporary "patient blood management".

For more information, see www.brandenburg-kapital.de and www.lindis-bloodcare.com